Targeted protein degradation (TPD) is a promising strategy for both therapeutics and research, providing new opportunities to overcome some of the current limitations associated with traditional small-molecule therapeutics, RNA interference (RNAi) and genome editing approaches. Proteolysis-targeting chimeras (PROTACs) are typically heterobifunctional molecules which bring a protein of interest (POI) into spatial proximity of an E3 ubiquitin ligase, triggering POI ubiquitylation and proteasomal degradation. The Sapkota lab previously developed an affinity-directed protein missile (AdPROM) system for...